Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Symptoms and General Pathology

Rare Diseases

Leukemia

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

All Drugs and Chemicals

Antineoplastic Agents

Antirheumatic Agents

Antibodies

Antibodies, Monoclonal

Bendamustine Hydrochloride

Rituximab

Immunoglobulins

Alkylating Agents

Antineoplastic Agents, Immunological

Immunologic Factors

Antineoplastic Agents, Alkylating

Previously untreated CLL requiring therapy according to the NCI criteria and treated with at least one cycle of BR as first-line treatment.

CLL that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the NCI criteria and treated with at least one cycle of BR.

Bendamustine + Rituximab

Antonio Cuneo

Gian Matteo Rigolin

This study is intended for Chronic Lymphocytic Leukemia patients who have already undergone a first or second treatment with drugs named bendamustine and rituximab. It will observe the results of this treatment and evaluate its efficacy and side effects.

This cohort study will recruit chronic lymphocytic leukemia (CLL) patients who were treated with first and second-line Bendamustine plus Rituximab (BR) from January 2008 to December 2014 from European centres adhering to the GIMEMA group and the ERIC group, and aims at observing the progression-free survival in CLL patients.

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia

Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia

Gruppo Italiano Malattie EMatologiche dell'Adulto

Lymphoma

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, B-Cell, Marginal Zone

Disease Progression

Lymphoma, Non-Hodgkin

Lymphoma, B-Cell

Lymphosarcoma

Mantle Cell Lymphoma

Follicular Lymphoma

Marginal Zone Lymphoma

B-cell Lymphoma

Anti-Infective Agents

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Vincristine

Immunosuppressive Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Tubulin Modulators

Antimitotic Agents

Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w

Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w

Comparison of Bendamustine + Rituximab with CHOP + Rituximab

Bendamustine

Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy

Standard chemotherapy CHOP + Ritiximab

Mathias Rummel, Dr.

The study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus rituximab with regard to progression free survival (PFS).

The 4 agent chemotherapy (CTX) CHOP (cyclophosphamide, doxorubicin, vincristine prednisone) in combination with the monoclonal anti-CD20 antibody rituximab (CHOP-R) represents a standard CTX for the treatment of lymphomas of high or low malignancy. The combination of bendamustine and rituximab (B-R) is also highly effective with a more advantageous toxicity profile. If B-R could be shown to be non inferior to CHOP-R, this could improve the quality of life of the patient and possibly also the prognosis.

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas

University of Giessen

Study Group indolent Lymphomas (StiL)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia	NCT02491398	Chronic Lymphoc...	Bendamustine + ...	18 Years -	Gruppo Italiano Malattie EMatologiche dell'Adulto
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab	NCT00991211	Non-Hodgkin Lym... Follicular Lymp... Immunocytomas Lymphocytic Lym... Marginal Zone L...	Bendamustine Standard chemot...	18 Years -	University of Giessen
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia	NCT02491398	Chronic Lymphoc...	Bendamustine + ...	18 Years -	Gruppo Italiano Malattie EMatologiche dell'Adulto

Spots Global Cancer Trial Database for bendamustine + rituximab